• 0Shopping Cart
XL-protein offers PASylation, a biological alternative to PEGylation
  • About
    • Corporate overview
    • Leadership team
  • Technology
    • Overview
    • Applications
      • Eye diseases
      • Cytokines
      • Enzymes
      • Peptides
      • Antibody fragments
      • Nanoparticles
      • In vivo imaging
      • AnimalHealth
    • PAS-Advantages
    • Intellectual property
  • Partnering
    • Partnering
  • News & Publications
    • Press Releases
    • Receive our Press Releases
    • Partner’s Press Releases
    • Key publications
    • Various publications
  • Careers
  • Contact
    • Contact
    • Imprint
    • Disclaimer
  • PAS-Shop
    • Products
    • Terms & Conditions
    • Privacy Policy
    • Shipping
  • Search
  • Menu Menu

AdAlta and XL-protein announce collaboration to develop a long acting version of its lead fibrosis drug candidate AD-114 using PASylation® Technology

7. November 2016
Melbourne, Australia and FREISING, Germany, 7 November 2016:…
https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png 0 0 web28627236 https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png web286272362016-11-07 09:40:132017-07-26 23:15:50AdAlta and XL-protein announce collaboration to develop a long acting version of its lead fibrosis drug candidate AD-114 using PASylation® Technology

Akari Therapeutics Plc and XL-protein GmbH Sign License Agreement to Develop a Long Acting Version of Coversin Using PASylation® Technology

14. June 2016
NEW YORK, LONDON, and FREISING, Germany, April 14, 2016 - Akari…
https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png 0 0 web28627236 https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png web286272362016-06-14 07:15:462016-09-27 09:17:51Akari Therapeutics Plc and XL-protein GmbH Sign License Agreement to Develop a Long Acting Version of Coversin Using PASylation® Technology

DNX Biopharmaceuticals and XL-protein Enter into a Shareholder Agreement to Develop and Commercialize Novel Long Acting Biopharmaceuticals.

1. February 2016
Irvine, California, and Freising, Germany, February 1, 2016 On…
https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png 0 0 web28627236 https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png web286272362016-02-01 23:01:472016-09-25 17:09:47DNX Biopharmaceuticals and XL-protein Enter into a Shareholder Agreement to Develop and Commercialize Novel Long Acting Biopharmaceuticals.
Page 6 of 11«‹45678›»
© 2021 - All Rights Reserved for XL-protein GmbH | Imprint | Disclaimer | Data Privacy Policy | Terms & Conditions
  • Mail
Scroll to top